Treatment options for
metastatic urothelial carcinoma:
Improve your knowledge and confidence in immunotherapy strategies for mUC with this set of three eLearning modules. Expert authors Axel Merseburger, Marc-Oliver Grimm and Simon Chowdhury will cover clinical trial data and real-world evidence to help you support your decisions regarding first-line, maintenance, and subsequent-line therapy, including the importance of predictive factors for treatment selection.
Our eLearning modules will cover the following topics:
- Immunotherapy options in first-line and maintenance therapy for patients with mUC
- Subsequent-line therapy options for patients with mUC
- Use of predictive factors for an optimal selection of maintenance therapy in patients with mUC
Each module will take up to 20 minutes to complete. In support of improving patient care, this activity has been planned and implemented by HMP Education and Springer Healthcare IME and will be certified with 1.00 AMA PRA Category 1 Credit ™.
If you would like to receive accreditation for your participation in these eLearning activities you must fill out the evaluation form at the end of each module. Having completed all three modules you will then be able to claim your credits.
Activity 1: Immunotherapy options in first-line and maintenance therapy for patients with mUC
In this eLearning video module, Marc-Oliver Grimm will outline available and emerging immunotherapy options in first-line for patients with metastatic UC and describe the potential of immunotherapy in the maintenance setting, as well as analyze the clinical data supporting these strategies.
Activity 2: Immunotherapy in advanced urothelial cancer: second-line and beyond
In this eLearning video module, Simon Chowdhury will explain the standard of care with immunotherapy in second- and subsequent treatment lines, reviewing potential factors that can influence treatment decisions in these settings.
Activity 3: Use of predictive factors for optimal selection of maintenance therapy in patients with mUC
In this eLearning video module, Axel Merseburger will discuss the need to develop a process to guide patient selection in order to achieve superior outcomes and evaluate clinical data behind potential predictive factors that could change the management of metastatic UC.
In support of improving patient care, this activity has been planned and implemented by HMP Education and Springer Healthcare IME. HMP Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
HMP Education designates this eLearning programme for a maximum of 1.00 AMA PRA Category 1 Credit ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
About these activities
After participating in this program, participants will be able to:
- Discuss current and emerging immune-based regimens for mUC and the clinical data supporting them
- Describe the current standard of care for second-line mUC and debate how to integrate and/or combine new immunotherapy options in this setting
- Analyze new treatment options for maintenance therapy and evaluate predictive factors, such as biomarkers, that could inform patient selection
This independent programme is supported by an educational grant from Pfizer and Merck Healthcare KGaA, Darmstadt, Germany
All content has been developed independently by Springer Healthcare IME, in conjunction with an expert Faculty.